Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While financial performance shows improvements in cost management and revenue growth, the company's guidance and liquidity concerns raise uncertainties. The Q&A section highlights potential growth in myelofibrosis treatment but lacks clarity on financing and market positioning. The absence of a strong catalyst like a new partnership or record revenue tempers expectations, resulting in a neutral sentiment.
Key Financial Performance
Total Revenue $44 million, an increase of 13.4% year-over-year. This growth was driven by higher milestone revenue from partners and increased U.S. net product revenue.
U.S. XPOVIO Net Product Revenue $32 million, an increase of 8.5% year-over-year. This growth reflects the continued strength of XPOVIO in multiple myeloma and disciplined execution of commercial and operational teams.
Gross to Net Provisions for XPOVIO 27% in Q3 2025, down from 31% in Q3 2024. This reduction reflects improved pricing and reimbursement strategies.
License and Other Revenue $12 million, up nearly 30% from Q3 2024. This increase was primarily driven by higher milestone revenue from the partner Menarini.
Research and Development Expenses $30.5 million, down 16% year-over-year. The decrease was driven by lower clinical trial costs for selinexor in multiple myeloma and reduced personnel and stock-based compensation expenses.
Selling, General, and Administrative Expenses $26.6 million, down 4% year-over-year. This decrease was due to cost reduction initiatives.
Loss from Operations Improved by approximately 42% year-over-year. This improvement reflects disciplined expense management and increased revenue.
Interest Expense $11 million in Q3 2025, compared to $11.4 million in Q3 2024. This slight decrease reflects refinancing efforts.
Other Expense $7.4 million in Q3 2025, compared to $3.8 million of other income in Q3 2024. This change was driven by noncash fair value remeasurements of embedded derivatives and liability-classified common stock warrants.
Net Loss $33.1 million or $3.82 per share on a GAAP basis. More than half of this loss is driven by below-the-line items, including interest expense and noncash mark-to-market adjustments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Phase III SENTRY trial completion: Enrollment completed for the Phase III SENTRY trial in frontline myelofibrosis, focusing on selinexor plus ruxolitinib as a potential all-oral treatment option. Top-line results expected in March 2026.
XPO1 inhibition mechanism: XPO1 inhibition targets multiple pathways, potentially overcoming limitations of current JAK inhibitors like ruxolitinib.
Myelofibrosis market opportunity: Potential peak revenue of $1 billion annually in the U.S. for selinexor plus ruxolitinib combination therapy. Target market includes 4,000 newly diagnosed intermediate to high-risk myelofibrosis patients annually in the U.S.
XPOVIO revenue growth: U.S. net product revenue grew 8.5% year-over-year to $32 million in Q3 2025, driven by its use in multiple myeloma.
Financial flexibility: Secured approximately $100 million through refinancing and capital restructuring, extending cash runway into Q2 2026.
Cost management: Reduced R&D and SG&A expenses, improving operational efficiency and lowering operating loss by 42% year-over-year in Q3 2025.
Focus on late-stage clinical programs: Prioritizing SENTRY and EC-042 trials, aiming for transformative outcomes in myelofibrosis and endometrial cancer.
Commercial readiness for myelofibrosis: Preparing for a potential launch of selinexor plus ruxolitinib combination therapy, leveraging existing commercial infrastructure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The multiple myeloma market is highly competitive, with XPOVIO facing challenges in maintaining and growing its market share. The company must contend with established therapies and new entrants, which could impact revenue growth.
Regulatory Risks: The success of the Phase III SENTRY trial and subsequent regulatory approval for selinexor in combination with ruxolitinib is critical. Any delays or negative outcomes in the trial could significantly impact the company's strategic plans and financial performance.
Financial Sustainability: While the company has extended its cash runway into Q2 2026, it remains reliant on successful commercialization of selinexor and other products to sustain operations. Failure to achieve projected revenues could lead to financial strain.
Clinical Trial Risks: The ongoing Phase III SENTRY trial carries inherent risks, including the possibility of not meeting primary endpoints or encountering unforeseen safety issues, which could derail the company's plans for selinexor in myelofibrosis.
Supply Chain and Operational Risks: The company must ensure a reliable supply chain and operational efficiency to support the potential launch of selinexor in combination with ruxolitinib. Any disruptions could delay commercialization and impact revenue.
Economic and Market Conditions: Broader economic uncertainties and market conditions could affect the company's ability to secure funding, maintain profitability, and achieve its strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III SENTRY trial in frontline myelofibrosis: Enrollment completed with top-line results expected in March 2026. The trial aims to redefine the standard of care for myelofibrosis through the combination of selinexor and ruxolitinib, potentially establishing a new paradigm for treatment.
Financial guidance: The company expects total revenue for 2025 to be between $140 million and $155 million, with U.S. XPOVIO net product revenue projected at $110 million to $120 million. Existing liquidity is expected to fund operations into Q2 2026.
Commercial opportunity in myelofibrosis: The potential peak revenue opportunity for selinexor in combination with ruxolitinib is estimated at $1 billion annually in the U.S. The target market includes approximately 4,000 newly diagnosed intermediate to high-risk myelofibrosis patients annually.
Selinexor's potential in myelofibrosis: The combination therapy with ruxolitinib is expected to improve spleen volume reduction, symptom improvement, and lower rates of Grade 3+ anemia. Preliminary data suggests meaningful efficacy and a manageable safety profile.
Strategic focus areas: The company is prioritizing advancing late-stage clinical programs (SENTRY and EC-042), driving growth in the XPOVIO franchise, and maintaining financial discipline to position for sustained success.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What level of detail will be provided for MF data in March 2026?
A:The top-line results expected in March 2026 will include primary endpoints such as SVR35 at week 24, absolute TSS, and potentially other secondary endpoints like hemoglobin and/or disease modification. Safety details will also be touched upon, with more granular details provided closer to the milestone.
Q:What is the strategy for the sales force and ex-U.S. markets for MF?
A:The company expects minimal additions to its commercial structure due to strong overlap with the current organization. For ex-U.S. markets, they will continue working with partners to drive launches and generate additional royalty and milestone revenues globally. Japan is the only market without a current partner.
Q:Are there any milestones or warrants associated with the recent financial restructuring that could extend capital beyond the second quarter?
A:There are no specific triggers from a financing perspective related to positive MF data. However, pending positive data, the company expects a strong inflection and value point. Globally, partnerships are well-established except for Japan, which remains unpartnered.
Q:How does the baseline TSS number of 22.5% impact the read-through from Phase I to Phase III?
A:The baseline TSS of 22.5% is higher than Phase I and other contemporary trials, suggesting a potentially meaningful improvement for absolute TSS with the combination therapy compared to ruxolitinib alone.
Q:What is the impact of baseline platelet count on activity and outcomes?
A:More than half of the patients have baseline platelet counts above 200,000. There is no biological or mechanistic reason to suggest that platelet count significantly impacts SVR35 rate or absolute TSS. The baseline characteristics are consistent with other Phase III trials.
Q:What data will be presented at ASH, and what will be included in the abstract?
A:The ASH presentation will include an abstract only, showing baseline characteristics among 320 patients. Additional data for the full ITT will be presented with the top-line results in March 2026.
Q:What are the findings from the blinded safety review of 61 patients?
A:The treatment-emergent adverse events (TEAEs) leading to discontinuation are stable over time, suggesting most events occur early. The data is encouraging, but final results will be available with the top-line data.
Q:What are the market research findings regarding the 75% intent to treat with the combo in frontline MF?
A:The target patients are newly diagnosed intermediate to high-risk patients with platelet counts above 100,000. The combination therapy is seen as an addition to ruxolitinib, not a competitor. Payer feedback aligns with physician intent, and there is significant appetite for combination treatments.
Q:What are the learnings from the multiple myeloma experience that are being applied to myelofibrosis?
A:Key learnings include using a lower dose of selinexor (60 mg once weekly) and dual antiemetics to manage nausea. These adjustments have improved tolerability and patient outcomes. The myelofibrosis space has less competition and is poised for transformation similar to what was seen in multiple myeloma over a decade ago.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about specific financing triggers or milestones that could extend capital beyond the second quarter. Additionally, they did not provide detailed insights into the potential impact of new targeted treatments on selinexor's positioning in the evolving myelofibrosis space.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Grade anemia
III SENTRY
Karyopharm
NF kappa
Phase III
STAT
TSS fatigue
VAF
area selinexor
beta
bone marrow
burden
cancer mutation
clone
disease
fatigue baseline
financing
frontline myelofibrosis
item
loss
marrow fibrosis
myelofibrosis Slide
opportunity standard
patient myelofibrosis
patient ruxolitinib
proliferation
rate Grade
risk
ruxolitinib patient
score
selinexor ruxolitinib
spleen volume
transaction
treatment driver
year
KPTI Transcript
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary provides a mixed outlook. The company shows positive financial performance with increased revenue and improved net loss figures. However, the critical dependency on the Phase III SENTRY trial results introduces significant risk, as negative outcomes could impact strategic objectives. Additionally, no shareholder return plans were discussed, and cash reserves have decreased. The Q&A section did not provide further insights to shift sentiment. Overall, the balance of positive financials and potential risks leads to a neutral sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call reflects strong financial guidance, a promising Phase III trial for myelofibrosis, and a strategic focus on growth and financial discipline. Q&A insights highlight positive analyst sentiment and manageable safety profiles. Despite some uncertainties in management responses, the optimistic outlook on selinexor's potential and strategic market positioning suggests a positive stock reaction. The absence of negative catalysts like guidance cuts or financial distress further supports a positive sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call presents a mixed outlook. While financial performance shows improvements in cost management and revenue growth, the company's guidance and liquidity concerns raise uncertainties. The Q&A section highlights potential growth in myelofibrosis treatment but lacks clarity on financing and market positioning. The absence of a strong catalyst like a new partnership or record revenue tempers expectations, resulting in a neutral sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reflects a mixed sentiment. While the company reports decreased R&D and SG&A expenses, an increase in interest expense and a significant net loss raise concerns. The Q&A highlights management's optimism about future trials, yet lacks specifics on enrollment and liquidity strategies. The positive outlook on new data readouts and potential market opportunities is tempered by financial challenges. These mixed signals suggest a neutral impact on stock price, with no strong catalysts for a significant move in either direction.
KPTI Slides
KPTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
